Tudor Investment Corp ET AL Makes New $492,000 Investment in Alkermes plc (NASDAQ:ALKS)

Tudor Investment Corp ET AL bought a new stake in Alkermes plc (NASDAQ:ALKS) in the fourth quarter, Holdings Channel reports. The institutional investor bought 17,120 shares of the company’s stock, valued at approximately $492,000.

Several other hedge funds have also made changes to their positions in the business. Renaissance Technologies LLC raised its stake in Alkermes by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company’s stock valued at $157,568,000 after acquiring an additional 57,697 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Alkermes by 6.5% in the fourth quarter. American Century Companies Inc. now owns 3,450,707 shares of the company’s stock valued at $99,242,000 after purchasing an additional 209,740 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Alkermes by 4.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company’s stock worth $86,842,000 after purchasing an additional 128,701 shares during the last quarter. Avoro Capital Advisors LLC acquired a new stake in shares of Alkermes during the fourth quarter worth $70,462,000. Finally, Loomis Sayles & Co. L P lifted its holdings in shares of Alkermes by 22.3% during the fourth quarter. Loomis Sayles & Co. L P now owns 2,302,905 shares of the company’s stock worth $66,232,000 after purchasing an additional 419,969 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. StockNews.com cut shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Monday. Robert W. Baird lifted their price objective on Alkermes from $38.00 to $41.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. The Goldman Sachs Group increased their target price on Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Deutsche Bank Aktiengesellschaft upped their price objective on Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. Finally, HC Wainwright restated a “neutral” rating on shares of Alkermes in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $38.33.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now owns 57,875 shares in the company, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.40% of the stock is owned by company insiders.

Alkermes Trading Up 0.0 %

Shares of ALKS stock opened at $30.40 on Friday. The company has a market cap of $5.01 billion, a PE ratio of 14.01, a P/E/G ratio of 2.20 and a beta of 0.51. The company’s fifty day simple moving average is $31.04 and its 200-day simple moving average is $30.51. Alkermes plc has a 52 week low of $22.90 and a 52 week high of $36.45.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.19). The company had revenue of $306.51 million for the quarter, compared to analyst estimates of $307.53 million. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The company’s revenue for the quarter was down 12.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.43 EPS. Equities research analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.